Luxupram Tablets (Escitalopram Oxalate)

Adult dosage

The safety of doses exceeding 20mg per day has not been established. This drug is administered once daily in the morning or evening, with or without food. 1) Adults (1) Major depressive disorder: The usual dose is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. If the dose of this drug is to be increased to 20mg, it should be increased at intervals of at least 1 week. In general, 2-4 weeks are needed for antidepressant effects to become apparent. Even after symptoms have resolved, at least 6 months of drug treatment is needed to ensure a therapeutic effect. (2) Panic disorder with or without agoraphobia: It is recommended to administer an initial dose of 5mg per day for 1 week, then increase the dose to 10mg per day. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. The maximum effect appears after approximately 3 months. The safety and efficacy of long-term administration of this drug for more than 10 weeks in the treatment of panic disorder have not been systematically studied. The physician should periodically reevaluate each patient to determine the need for continued treatment. (3) Social anxiety disorder: The usual dose is 10mg once daily. In general, 2-4 weeks are needed for symptoms to improve. Thereafter, depending on the patient's response, the dose may be reduced to 5mg per day or increased to a maximum of 20mg per day. Social anxiety disorder is a chronic condition, and continued treatment for 12 weeks is recommended to ensure a therapeutic effect. Long-term treatment in patients who respond has been studied for 6 months, and should be considered on an individual patient basis to prevent relapse. The usefulness of long-term treatment should be periodically reevaluated. (4) Generalized anxiety disorder: The initial dose is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day after at least 1 week of treatment. A long-term administration study was conducted in patients who responded to 12 weeks of open-label treatment, with 20mg per day administered for at least 6 months. The physician should periodically reevaluate the usefulness of long-term treatment with this drug for each patient. (5) Obsessive-compulsive disorder: The usual dose is 10mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20mg per day. A long-term administration study was conducted in patients who responded to 6 weeks of open-label treatment, with 10mg or 20mg per day administered for at least 24 weeks. Obsessive-compulsive disorder is a chronic condition, and this drug should be administered for a sufficient period to ensure recovery from symptoms. When this drug is administered long term, its usefulness and dosage should be periodically reevaluated for each patient. 2) Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Caution should be exercised in patients with severe renal impairment (CLCR < 30㎖/min). 3) Patients with hepatic impairment An initial dose of 5mg per day for the first 2 weeks is recommended. Depending on the patient's response, the dose may be increased to 10mg per day. 4) Discontinuation of treatment When discontinuing this drug, the dose should be gradually reduced over at least 1-2 weeks to avoid the possibility of withdrawal symptoms. 5) Switching from MAO inhibitors used to treat psychiatric disorders At least 14 days should elapse between discontinuing an MAO inhibitor used to treat psychiatric disorders and starting treatment with this drug. Conversely, at least 14 days should elapse after discontinuing this drug before starting an MAO inhibitor for the treatment of psychiatric disorders. 6) Other MAO inhibitors, such as linezolid or methylene blue Treatment with this drug should not be started in patients receiving linezolid or intravenous methylene blue because of the increased risk of serotonin syndrome. For patients requiring more urgent treatment of a psychiatric condition, including hospitalization, other interventions should be considered. It may be necessary to urgently administer linezolid or intravenous methylene blue to a patient already receiving this drug. If there is no alternative to linezolid or intravenous methylene blue and the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome in a particular patient, this drug may be discontinued immediately and linezolid or intravenous methylene blue administered. Patients should be monitored for symptoms of serotonin syndrome for 2 weeks after administration of linezolid or intravenous methylene blue, or until 24 hours after the last dose, whichever comes first. Treatment with this drug may be restarted 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with administration of methylene blue by non-intravenous routes (oral tablets or local injection), or with intravenous administration of this drug at 1mg/kg or less, is unclear. Nevertheless, clinicians should be aware of the possibility of emergency symptoms of serotonin syndrome with these uses.

This medication is an antidepressant used to treat psychiatric conditions such as major depression. There may be an increased risk of suicidal thoughts or behavior when prescribing this medication to children, adolescents, and young adults aged 18 to 24, thus healthcare professionals should carefully assess the necessity and risks of treatment. This medication should not be given to patients with hypersensitivity to the escitalopram component or those currently taking specific types of medication known as MAO inhibitors, and caution is also needed for patients with certain heart conditions or those taking specific drugs. Patients with angle-closure glaucoma or a history of glaucoma should be particularly cautious as this drug can cause pupil dilation and increase the risk of elevated intraocular pressure. During treatment with this medication, various side effects may present such as anxiety, insomnia, changes in appetite, dizziness, nausea, headache, and sexual dysfunction, particularly within the first 1-2 weeks of treatment. Discontinuation of this medication can cause withdrawal symptoms such as dizziness, anxiety, and sleep disturbances; therefore, it should be tapered off gradually under physician guidance. This medication can prolong the QT interval related to heart rhythm, hence patients with existing heart conditions or those taking related medications should have monitoring and use with caution. Additionally, taking this medication together with other serotonergic agents carries a risk of a serious and potentially life-threatening condition known as serotonin syndrome, hence consultation with healthcare professionals is essential. Pregnant or breastfeeding women should consult a doctor prior to taking this medication, especially in the later stages of pregnancy, as it could impact the newborn. Elderly patients are advised to start with a lower initial dosage and gradually adjust, and caution is advised when driving or operating machinery. The safety and efficacy of this medication have not been adequately established in children and adolescents, thus use in these populations is not recommended. Finally, when storing this medication, keep it out of reach of children and do not transfer it to another container.

Thrombocytopenia, anaphylactic reaction, inappropriate secretion of antidiuretic hormone, hyperprolactinemia, decreased appetite, increased appetite, weight gain, weight loss, hyponatremia, loss of appetite, anxiety, restlessness, abnormal dreams, decreased libido, sexual dysfunction, bruxism, agitation, irritability, panic attack, confusion, aggression, depersonalization, hallucination, mania, suicidal ideation, suicidal behavior, insomnia, drowsiness, dizziness, perceptual disturbances, tremor, taste disorder, sleep disturbances, syncope, serotonin syndrome, movement disorders, dyskinesia, convulsions, psychomotor agitation, akathisia, mydriasis, visual impairment, tinnitus, tachycardia, bradycardia, QT interval prolongation, polymorphic ventricular tachycardia, ventricular arrhythmia, orthostatic hypotension, sinusitis, yawning, nosebleed, nausea, diarrhea, constipation, vomiting, thirst, gastrointestinal bleeding, hepatitis, abnormal liver function tests, increased sweating, urticaria, hair loss, rash, pruritus, petechiae, angioedema, arthralgia, myalgia, rhabdomyolysis, urinary retention, ejaculation dysfunction, erectile dysfunction, uterine bleeding, heavy menstrual bleeding, galactorrhea, postpartum hemorrhage, priapism, fatigue, fever, edema, headache, dry mouth, abdominal pain, dyspepsia, enteritis, sensory abnormalities, cough, asthma, dyspnea, fracture, palpitations, hypertension, paralysis, extrapyramidal symptoms, migraine, chest pain, aggressive reaction, loss of appetite, hallucination, sexual dysfunction, drowsiness, insomnia, aggressive reaction, decreased libido, loss of appetite, hallucination, cough, asthma, dyspnea, weight gain, chest pain, fever, fracture, arthralgia, sexual dysfunction, palpitations, hypertension, dry mouth, abdominal pain, nausea, constipation, dizziness, decreased libido, weight gain, nausea, headache, constipation, dizziness, dry mouth, abdominal pain, insomnia, weight gain, fever, vomiting, dyspepsia, enteritis, sensory abnormalities, cough, sexual dysfunction, palpitations, diarrhea, paralysis, extrapyramidal symptoms, migraine, decreased libido, loss of appetite, hallucination, asthma, dyspnea, fracture, arthralgia, hypertension, headache, frequent urination, sedation, sweating, frequent urination, tremor, weight gain, abdominal discomfort, anxiety, visual hallucination, dizziness, sensory abnormalities, sleep disturbances, agitation, anxiety, nausea, vomiting, tremor, confusion, sweating, headache, diarrhea, palpitations, emotional instability, irritability, visual impairment, suicidal tendency, suicidal impulse, suicidal behavior, anxiety, agitation, panic disorder, insomnia, excitement, hostility, aggression, impulsivity, akathisia, hypomania, mania, hyponatremia, petechiae, purpura, postpartum hemorrhage, serotonin syndrome, dizziness, tremor, agitation, serotonin syndrome, convulsions, coma, nausea, vomiting, diarrhea, hypotension, tachycardia, QT interval prolongation, arrhythmia, hypokalemia, hyponatremia, headache, dizziness, drowsiness, gastrointestinal disturbances, heartburn, sedation, thirst, decreased libido, decreased appetite, dry mouth, dyspepsia, sweating, frequent urination, sexual dysfunction, tremor, weight gain, abdominal discomfort, anxiety, insomnia, visual hallucination

This medication is sensitive to light and should be stored in a container that protects it from light. It is best to store it at room temperature between 1 degree and 30 degrees Celsius. Proper storage can maintain the medication's efficacy and prevent deterioration.

Appearance

White oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle